Dramatic Reduction: Eli Lilly's experimental drug, lepodisiran, reduced Lp(a) levels by up to 94% in a Phase 2 trial (ALPACA study).
Long-Lasting Effect: The reduction was sustained for nearly 1.5 years after two doses in some participants.
Widespread Risk: High Lp(a) is common, affecting roughly 1 in 5 people globally (around 64 million adults in the U.S.) and is determined by genetics, not lifestyle.
Serious Consequences: Elevated Lp(a) can double or triple the risk of heart attack, stroke, and aortic valve narrowing.
Why this matters: This research marks a critical step towards the first effective treatment for high Lp(a), potentially preventing countless cardiovascular events in genetically predisposed individuals.
Lipoprotein(a) is often called 'stealthy' cholesterol because it's not measured in routine cholesterol panels and isn't significantly affected by diet, exercise, or current cholesterol medications like statins. Its danger lies in a triple threat:
It enhances the artery-clogging potential of LDL ('bad') cholesterol.
It promotes inflammation in blood vessels.
It increases the tendency for blood clots to form.
Many individuals, like Donald Kosec mentioned in reports, discover they have high Lp(a) only after experiencing a major cardiovascular event, despite having otherwise normal risk profiles.
Lepodisiran utilizes a cutting-edge technology called small interfering RNA (siRNA). It works by intercepting the genetic instructions (messenger RNA or mRNA) that tell the liver to produce apolipoprotein(a), the key protein component of Lp(a). By 'shooting the messenger,' the drug effectively halts Lp(a) production at its source.
The Phase 2 ALPACA study, funded by Eli Lilly and published in the *New England Journal of Medicine*, involved 320 participants with elevated Lp(a). Key findings presented at the American College of Cardiology 2024 Scientific Sessions include:
A single 400mg dose reduced Lp(a) by an average of 93.9% between day 60 and 180.
Participants receiving two 400mg doses (at baseline and day 180) saw sustained reductions, remaining 74.2% below baseline at day 540 (nearly 1.5 years).
The drug was generally well-tolerated, with no serious adverse events directly linked to treatment.
Dr. Steven Nissen, lead researcher from the Cleveland Clinic, called the results "remarkable," highlighting that clinicians have previously been unable to effectively treat Lp(a).
Lepodisiran is now advancing to a large-scale Phase 3 trial (ACCLAIM-Lp(a)). This trial will assess whether the significant Lp(a) reduction translates into fewer heart attacks, strokes, and other cardiovascular events over the long term.
Individuals with:
A personal or family history of premature heart disease (heart attack or stroke before age 55 in men, 65 in women).
Recurrent cardiovascular events despite well-managed traditional risk factors (like LDL cholesterol, blood pressure).
A diagnosis of aortic valve stenosis.
Known elevated Lp(a) levels.
Approximately 20-25% of the global population falls into the high-Lp(a) category.
While specific Lp(a)-lowering drugs like lepodisiran are still investigational:
Discuss Testing: Talk to your doctor about Lp(a) testing, especially if you fit the high-risk profiles mentioned above. Knowing your level is the first step.
Manage Other Risks: Continue diligently managing all other cardiovascular risk factors: control blood pressure, lower LDL cholesterol if needed, manage diabetes, avoid smoking, maintain a healthy weight, eat a heart-healthy diet, and exercise regularly.
Stay Informed: Keep abreast of developments in Lp(a) research and the progress of clinical trials like ACCLAIM-Lp(a).
Q: What is Lipoprotein(a) or Lp(a)?
A: Lp(a) is a specific type of cholesterol particle in the blood. Its level is primarily determined by your genes and high levels are strongly linked to an increased risk of heart attacks, strokes, and aortic valve disease. It is not routinely measured in standard cholesterol tests.
Q: Why haven't doctors treated high Lp(a) before?
A: Until recently, there were no effective treatments specifically designed to lower Lp(a) levels significantly. Lifestyle changes and existing cholesterol drugs have minimal impact on it.
Q: How does lepodisiran work?
A: It is an investigational RNA interference (siRNA) therapy. It targets and silences the messenger RNA (mRNA) responsible for producing apolipoprotein(a), a key building block of Lp(a), thereby lowering its levels in the blood.
Q: When will lepodisiran be available?
A: Lepodisiran is still under investigation in Phase 3 clinical trials. It needs to successfully complete these trials and receive approval from regulatory agencies like the FDA before it can become available for prescription. This process typically takes several years.
A major genetic risk factor for heart disease, high Lp(a), may soon be treatable thanks to new drugs like lepodisiran.
If you have a personal or family history of early heart disease, consider discussing Lp(a) testing with your healthcare provider.
While these new therapies are developed, focusing on controlling traditional cardiovascular risk factors remains essential for heart health.
The success of lepodisiran in early trials represents a significant potential breakthrough in preventing heart disease for millions.
Could drugs like lepodisiran finally neutralize this 'stealthy' genetic heart risk? Share your thoughts below!
Share this article with others who need to stay ahead of this trend!
Share on Twitter/X target="_blank" | Share on LinkedIn target="_blank" | Share on Reddit target="_blank"
NBC News: One dose of experimental drug nearly wipes out stealthy cholesterol in 'remarkable' trial
Eli Lilly and Company: Lilly's lepodisiran reduced levels of genetically inherited heart disease risk factor, lipoprotein(a)...
Nissen, S. E., et al. (2024). Lepodisiran for Apoprotein(a) Lowering. *New England Journal of Medicine*. (Published online March 30, 2024)
⚠ Disclaimer: Yanuki provides article summaries and links for reference only. Yanuki does not endorse, verify, or guarantee the accuracy of third-party sources. Please review original sources and verify information independently. Managed by the Yanuki Data Engine. Full Disclaimer